BioSpace News Archive

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”) today announced that Dr. Jonathan Javitt, Founder and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the Noble Capital Markets’ 19th Annual Emerging Growth Investor Conference on Monday, December 4th, 2023, at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th at 5:05 pm ET.

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to Carole Huntsman, the Company’s new Chief Commercial Officer and Senior Vice President and twelve other new employees, in each case with a grant date of November 20, 2023, as equity inducement awards under the terms of the company’s 2023 Inducement Plan.

Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.

RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase II, open-label, multicenter, single-arm studies for Disitamab Vedotin (RC48-C005 and RC48-C009) have demonstrated consistent efficacy in patients with HER2-positive (immunohistochemistry 3+ or 2+) locally advanced or metastatic urothelial carcinoma (mUC) who have progressed through at least one previous line of systemic chemotherapy.